article thumbnail

Personalized medicine in a community health system: the Endeavor Health experience [Dissemination and implementation research]

Annals of Family Medicine

In 2014, Endeavor Health (formerly NorthShore University HealthSystem) launched the Center for Personalized Medicine to catalyze the delivery of personalized medicine. The development of a novel bioinformatics platform (FLYPE) enabled the incorporation of genomics data into electronic medical records.

Community 130
article thumbnail

Empowerment Self-Defense Arms ED Staff Against Rising Workplace Violence

Physician's Weekly

For physicians, nurses, medical assistants, and support staff, workplace violence (WPV) is now a daily hazard, inflicting physical injury, emotional trauma, and eroding the quality of patient care. Current Responses: Necessary but Insufficient Medical organizations have responded with advocacy efforts and public campaigns.

59
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Family Medicine: Finding Its Way on the Federal Research Roadmap [Economic or policy analysis]

Annals of Family Medicine

Setting or Dataset: Data encompassed awards from various federal agencies, predominantly including the US National Institutes of Health and others from 2014-2023. Population Studied: US DFMs Intervention/Instrument: The NIH RePORTER and Liaison Committee on Medical Education (LCME) databases.

DO 130
article thumbnail

DEA Regs Bulk Up with 2014 Anabolic Steroid Control Law Additions

FDA Law Blog

Houck — Anabolic steroids that include testosterone, methyltestosterone, nandrolone decanoate and oxandrolone are schedule III controlled substances with currently accepted medical uses in the U.S. Implementation of the Designer Anabolic Steroid Control Act of 2014 , 88 Fed. DASCA became law, amending the CSA, on December 18, 2014.

article thumbnail

FDA Publishes Discussion Paper Seeking Feedback on 3D Printing of Medical Devices at the Point of Care

FDA Law Blog

Cato — On December 10, 2021, FDA issued a discussion paper titled 3D Printing Medical Devices at the Point of Care seeking feedback on FDA regulatory oversight of various 3D-printing scenarios, in order to inform future policy development. products intended for medical purposes). use in education, construction, art, and jewelry).

Medical 98
article thumbnail

GeneSight® Mental Health Monitor Results

Myriad Genetics

The majority of these patients (54%) agree that genetic testing for mental health medications (known as pharmacogenomic or PGx testing) could reduce these concerns. The majority of these patients (54%) agree that genetic testing for mental health medications (known as pharmacogenomic or PGx testing) could reduce these concerns.

article thumbnail

FDA Publishes Discussion Paper Seeking Feedback on 3D Printing of Medical Devices at the Point of Care

FDA Law Blog

Cato — On December 10, 2021, FDA issued a discussion paper titled 3D Printing Medical Devices at the Point of Care seeking feedback on FDA regulatory oversight of various 3D-printing scenarios, in order to inform future policy development. products intended for medical purposes). use in education, construction, art, and jewelry).

Medical 75